RSS Feeds
Treatment of Waldenstrom Macroglobulinemia with 2-Chlorodeoxyadenosine
- Meletios A. Dimopoulos, MD;
- Hagop Kantarjian, MD;
- Elihu Estey, MD;
- Susan O'Brien, MD;
- Kay Delasalle, BS;
- Michael J. Keating, MBBS;
- Emil J. Freireich, MD; and
- Raymond Alexanian, MD
- From the University of Texas M. D. Anderson Cancer Center, Houston, Texas. Requests for Reprints: Meletios A. Dimopoulos, MD, University of Texas M. D. Anderson Cancer Center, Box 1, 1515 Holcombe Boulevard, Houston, TX 77030. Acknowledgments: The authors thank Dean Anthony and Rose Guevara for preparing and editing this manuscript. Grant Support: In part by the Hompe Myeloma Research Fund.
Abstract
Objective: To evaluate the activity of 2-chlorodeoxyadenosine (2CdA) in the treatment of patients with Waldenstrom macroglobulinemia.
Design: Uncontrolled phase II trial.
Setting: Tertiary, referral cancer center.
Patients: Twenty-nine consecutive, symptomatic patients with Waldenstrom macroglobulinemia, of whom 9 were previously untreated.
Intervention: 2-Chlorodeoxyadenosine was administered as a continuous intravenous infusion at a dose of 0.1 mg/kg body weight per day for 7 days. Only two courses of 2CdA were given and responding patients were then followed without further treatment.
Measurements and Main Results: A total of 17 (59%) patients responded, including all of those who were newly diagnosed and 40% of those who had failed previous therapies. Treatment was well tolerated except for one death in a patient who had presented with severe pancytopenia. With a median follow-up of 7 months, only one responding patient has relapsed.
Conclusion: 2-Chlorodeoxyadenosine is a nucleoside analog that was effective in most patients with Waldenstrom macroglobulinemia and was associated with little toxicity.
- Copyright ©2004 by the American College of Physicians
Related Clinical Content
